Research location

Heidelberg

Victoria, Australia

Published trials270

Site observations271

Linked trials published270

Page1 / 6

Research activity in Heidelberg

Victoria, Australia

CureCurrent currently publishes aggregate city-level research activity for this location: 270 trials and 271 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Heidelberg

270 linked trials · page 1 of 6

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT07680764 · 2026-09-10 · 1 site observation

Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)NCT07287202 · 2026-07-14 · 1 site observation

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate CancerNCT07567846 · 2026-04-29 · 1 site observation

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesNCT07351058 · 2026-03-23 · 1 site observation

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesNCT07351045 · 2026-03-16 · 1 site observation

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)NCT07282574 · 2026-03-10 · 1 site observation

Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASNCT07435038 · 2026-01-29 · 1 site observation

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsNCT07185997 · 2025-12-17 · 1 site observation

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid TumorsNCT07222267 · 2025-12-11 · 1 site observation

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisNCT07225504 · 2025-11-11 · 1 site observation

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerNCT07085767 · 2025-11-03 · 1 site observation

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06793215 · 2025-10-24 · 1 site observation

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)NCT06926868 · 2025-09-11 · 1 site observation

Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA StudyNCT07055542 · 2025-08-27 · 1 site observation

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant TumorsNCT07070232 · 2025-08-12 · 1 site observation

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's DiseaseNCT07094516 · 2025-08-07 · 1 site observation

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerNCT07005102 · 2025-08-03 · 1 site observation

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLCNCT06765109 · 2025-07-17 · 1 site observation

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease StudiesNCT07177352 · 2025-07-02 · 1 site observation

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis SpasticityNCT06782490 · 2025-06-05 · 1 site observation

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerNCT06712355 · 2025-02-03 · 1 site observation

Implementing Surgery School Prehabilitation Using TelehealthNCT06631872 · 2025-01-22 · 1 site observation

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 MutationsNCT06706076 · 2025-01-09 · 1 site observation

Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung CancerNCT06613009 · 2024-12-30 · 1 site observation

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)NCT06452277 · 2024-08-28 · 1 site observation

Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and PatientsNCT06324604 · 2024-06-13 · 1 site observation

A Study of MGC026 in Participants With Advanced Solid TumorsNCT06242470 · 2024-03-06 · 1 site observation

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsNCT06120283 · 2023-12-01 · 1 site observation

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400NCT06084481 · 2023-11-09 · 1 site observation

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate CancerNCT05800665 · 2023-05-02 · 1 site observation

Alleviant ALLAY-HF StudyNCT05685303 · 2023-01-10 · 1 site observation

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerNCT05267626 · 2022-04-04 · 1 site observation

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT04928846 · 2022-03-25 · 1 site observation

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid TumorsNCT04913285 · 2021-08-04 · 1 site observation

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsNCT04429542 · 2020-06-01 · 1 site observation

The EXCEL Registry of Patients Requiring ECMONCT03793257 · 2019-02-01 · 1 site observation

A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or ObesityNCT07861100 · 2026-10-26 · 1 site observation

NOT_YET_RECRUITING

Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using DapagliflozinNCT07225465 · 2026-02-01 · 1 site observation

NOT_YET_RECRUITING

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseaseNCT07170150 · 2025-11-12 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate CancerNCT06764485 · 2025-03-13 · 1 site observation

ACTIVE_NOT_RECRUITING

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLCNCT06745323 · 2025-02-26 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung CancerNCT06685718 · 2024-12-05 · 1 site observation

Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II DiabetesNCT06267391 · 2024-05-01 · 1 site observation

ACTIVE_NOT_RECRUITING

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard TreatmentNCT06151574 · 2024-02-09 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose WeightNCT06066528 · 2023-11-27 · 1 site observation

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightNCT06066515 · 2023-11-25 · 1 site observation

Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's DiseaseNCT06079190 · 2023-10-20 · 1 site observation

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)NCT05607550 · 2023-06-01 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local TherapiesNCT05794906 · 2023-04-03 · 1 site observation

ACTIVE_NOT_RECRUITING

Tucatinib Together With Pembrolizumab and TrastuzumabNCT04789096 · 2023-03-07 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.